Navigation Links
Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of 'Start Clean' Strategy

State of Victoria, Australia 'Start Clean' Strategy Requires Public

Reporting of HAIs in all 76 Public Hospitals by End of 2009

SUNNYVALE, Calif., July 28 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that the State of Victoria has selected Cepheid's GeneXpert(R) System and Xpert(TM) MRSA test for screening of high risk patients in up to 11 hospitals. Selection of these systems is part of ongoing efforts to comply with the rollout of the 5-year 'Start Clean' Victorian Infection Control Strategy, introduced by the Victorian Department of Human Services in 2007. To maintain compliance, all 76 Victorian public hospitals will need to provide public reporting of Healthcare Associated Infections (HAIs) by the end of 2009, according to the timelines published in the infection control strategy.

On-demand Xpert MRSA results enable Australian healthcare professionals to rapidly identify MRSA colonized patients entering the hospital population, thereby reducing risk of potential transmission. As quoted from the Start Clean Victorian Infection Control Strategy 2007-2011 document:

"Recent studies show that rapid diagnosis of MRSA colonization from screening swabs using PCR technology can reduce the time taken for detection of a carrier from days to hours. This is an important advance for the appropriate use of resources for the isolation and cohorting of patients."

"It is encouraging to note that Australian officials are recognizing the unique benefit of the GeneXpert System in providing clinically useful results on-demand," said John Bishop, Cepheid's Chief Executive Officer. "Faster time to result not only improves patient management, but also optimizes utilization of hospital resources."

The 'Start Clean' strategy introduced a pay for performance concept last year that began linking federal funding to compliance timelines for hospitals. The compliance strategy includes guidelines for screening, public reporting of HAIs, judicious use of antibiotics, hospital cleanliness and hand hygiene.

In addition to the current recommendation for the screening of all high-risk patients, as defined by the 2005 multi-resistant organism consensus conference, the 'Start Clean' strategy also allocates funds to help hospitals implement systems to rapidly diagnose MRSA and other significant organisms.

Other Australian states are closely monitoring the rollout of Victoria's 'Start Clean' strategy. Further trials are underway and are expected to be complete by the end of 2008. This may lead to the rollout of a similar strategy in other states.

About the GeneXpert Molecular Diagnostic System

The GeneXpert System is a closed, self-contained, fully-integrated and automated platform that represents a paradigm shift in the automation of molecular analysis, producing accurate results in a timely manner with minimal risk of contamination. The GeneXpert System is the only system to combine on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples. Modular in design, the GeneXpert System has a variety of configurations to meet the broad range of testing demands of any clinical environment.

About Cepheid

Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See for more information.

This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to product performance and utility, and future market opportunities in other states in Australia and timing of other trials. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: regulatory developments and practices regarding testing levels and best practices regarding testing and screening worldwide, and in Australia and the State of Victoria in particular; customer and market acceptance of the product; unforeseen manufacturing problems; the failure of products to perform as expected, whether due to manufacturing errors, defects or otherwise; the impact of competitive products and pricing; potentially lengthy sales cycles in some markets; the fact that there are no commitments to purchase any products by hospitals in Victoria or elsewhere in Australia, and there can be no assurance that they will do so in the future; and underlying market conditions. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.


For Media Inquiries: For Cepheid Investor Inquiries:

Jared Tipton Jacquie Ross

Cepheid Corporate Communications Cepheid Investor Relations

408-400-8377 Tel: (408) 400 8329

SOURCE Cepheid
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cepheid Launches New GeneXpert(R) Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus
2. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
3. PLC Systems Defers Pivotal Study of RenalGuard(TM) in the U.S.
4. Impliant Launches Less-Invasive Version of Patented TOPS(TM) Spine System
5. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
6. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
7. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
8. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
9. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
10. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
11. eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials
Post Your Comments:
(Date:12/1/2015)... 2015 Pharma Tech Outlook recently conducted a ... Data Management Solution Providers - 2015 .  After careful ... CEOs, CIOs, VCs, analysts, and the Pharma Tech Outlook ... top 10 clinical data management solution providers (check out ... and 36 respectively). --> ...
(Date:12/1/2015)... , 1 de diciembre de 2015 ... tecnología para cuchillas de precisión, develó hoy ... de identidad de marca. El nuevo logo ... diseño y la ingeniería de productos con ... diferencia". ...
(Date:12/1/2015)... -- Six months of adjunctive metformin therapy does not improve glycemic ... new research from T1D Exchange and funded by ... effect on measures of obesity, including weight and BMI. The ... of the American Medical Association , are from the largest ... overweight and obese adolescents with type 1 diabetes. ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... , ... Florida Hospital Tampa is the first health care provider in the region ... , vBloc® Therapy is a vagal blocking therapy, delivered via the Maestro® System, for the ... (BMI) of at least 40 to 45 kg, or a BMI of at least 35 ...
(Date:12/1/2015)... ... , ... Dr. Paul Vitenas, one of the top cosmetic surgeons in ... as the Best Single Physician Practice in the nation. Dr. Vitenas and his practice ... by the industry publication. , Dr. Vitenas said he was very honored to ...
(Date:12/1/2015)... ... 01, 2015 , ... CloudLIMS today announced that it is ... under the New Products and Services category for its innovative product offering, BioTracer. ... that helps labs organize data and track samples with storage inventories. BioTracer's ...
(Date:12/1/2015)... ... December 01, 2015 , ... For ... mark the film for accurate interpretation by the radiologist. The marking utensils are ... from Sacramento, Calif., has found a way to alleviate this problem. , He ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... announced it has been awarded a fixed price per sprint agile development contract ... valued at $34 million over five years, provides software engineering, infrastructure, as well ...
Breaking Medicine News(10 mins):